Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 2

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab

Authors Kim GP, Grothey A

Published 6 June 2008 Volume 2008:2(2) Pages 223—228

DOI https://doi.org/10.2147/BTT.S1980

George P Kim, Axel Grothey

College of Medicine, Mayo Clinic

Abstract: The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can succeed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment.

Keywords: colorectal cancer, chemotherapy, panitumumab, oxaliplatin, irinotecan, bevacizumab, cetuximab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]